TELA Bio price target lowered to $15 from $20 at JMP Securities

JMP Securities lowered the firm’s price target on TELA Bio to $15 from $20 and keeps an Outperform rating on the shares. Total Q3 sales were shy of the Street’s estimates, with management attributing the miss to recent upgrades to its commercial team, the analyst tells investors in a research note. The firm believes TELA offers a compelling portfolio that is well positioned for significant growth ahead.